- Previous Close
16.48 - Open
16.47 - Bid 16.78 x 200
- Ask 16.81 x 1200
- Day's Range
16.47 - 16.86 - 52 Week Range
10.71 - 17.44 - Volume
965,600 - Avg. Volume
1,297,137 - Market Cap (intraday)
4.758B - Beta (5Y Monthly) 2.07
- PE Ratio (TTM)
120.00 - EPS (TTM)
0.14 - Earnings Date Oct 30, 2024 - Nov 4, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
16.75
Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems. The company also provides microbiological and analytical chemistry testing, as well as technical assistance, regulatory consulting, and advisory services. It serves medical devices, pharmaceuticals, food safety, agricultural products, cancer treatment, and high-performance materials industries, as well as commercial, advanced, and specialty application industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2015 and is headquartered in Broadview Heights, Ohio.
soterahealth.com3,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: SHC
View More
Performance Overview: SHC
Trailing total returns as of 9/13/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SHC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SHC
View MoreValuation Measures
Market Cap
4.76B
Enterprise Value
6.86B
Trailing P/E
120.00
Forward P/E
20.49
PEG Ratio (5yr expected)
1.71
Price/Sales (ttm)
4.34
Price/Book (mrq)
11.25
Enterprise Value/Revenue
6.25
Enterprise Value/EBITDA
16.45
Financial Highlights
Profitability and Income Statement
Profit Margin
3.65%
Return on Assets (ttm)
7.66%
Return on Equity (ttm)
9.53%
Revenue (ttm)
1.1B
Net Income Avi to Common (ttm)
39.94M
Diluted EPS (ttm)
0.14
Balance Sheet and Cash Flow
Total Cash (mrq)
246.58M
Total Debt/Equity (mrq)
555.18%
Levered Free Cash Flow (ttm)
148.61M
Research Analysis: SHC
View MoreCompany Insights: SHC
SHC does not have Company Insights
Research Reports: SHC
View MoreRaising target price to $17.00
SOTERA HEALTH CO has an Investment Rating of HOLD; a target price of $17.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetWhat does Argus have to say about SHC?
SOTERA HEALTH CO has an Investment Rating of HOLD; a target price of $16.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of High.
RatingPrice TargetRaising target price to $16.00
SOTERA HEALTH CO has an Investment Rating of HOLD; a target price of $16.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of High.
RatingPrice TargetRaising target price to $16.00
SOTERA HEALTH CO has an Investment Rating of HOLD; a target price of $16.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice Target